Here are the latest stories being discussed in biopharma today:

Catalent’s Q2 Revenue Slumps Despite Novo Acquisition

Novo-backed Catalent reported a 10% drop in fiscal Q2 revenue, falling from $1.15 billion to $1.03 billion year-on-year. Although its biologics revenue dwindled 24% to $580 million, the pharmaceutical and consumer health sector fared slightly better, with revenue increasing by 1% from the same period last year to $587 million. This decline in earnings follows just days after Novo Holdings pledged to buy Catalent for $16.5 billion.

Synlogic Winding Down after Trial Setbacks

Synlogic is ending its synthetic biology pursuit due to its top candidate, SYNB1934, being unlikely to achieve success in the critical Phase III trials for phenylketonuria treatment. This has led Synlogic to the decision to stop operations and lay off most employees, retaining only a small team to help navigate strategic alternatives or dissolution.

Vicore Licenses IPF Treatment to Japanese Pharmaceutical Firm, Roche and Sensorion COVID-impacted

Despite adverse conditions, Vicore Pharma sold the Japan rights to its oral idiopathic pulmonary fibrosis drug C21, to Nippon Shinyaku for up to $275 million. Elsewhere, Roche is planning layoffs that would affect up to 340 employees globally, while Sensorion, an ear disorder biotech, has raised €50 million.

Takeda Picks Former CRISPR CMO to Lead Cancer-focused Unit and Other Peer Reviews

Takeda has chosen the former CMO of CRISPR to lead its oncology unit. At the same time, Emile Nuwaysir has left his position at Ensoma.

Preclinical Biotech Metagenomi Prices IPO at Bottom End

Preclinical biotech Metagenomi has priced its initial public offering (IPO) at the lower end of the proposed range, raising $94 million.

Kyverna’s Shares Surge after IPO – New Plans Unveiled for Cell Therapy in Immune Diseases

Kyverna’s shares experienced a surge following its IPO. The company’s CEO has since outlined new plans for cell therapy in immune diseases.